iMAb uses its proprietary phage display technology to deliver to pharmaceutical and biotech customers the antibodies with the desired characteristics, fit for continued drug development.
Each project is assigned to a dedicated team, focused on a single target at a time, to configure project plans and antibody selection schemes adjusted to the antigen and objectives.
iMAb works in tandem with its corresponding academic platform "GenAc" and Inserm lab for very active research and R&D collaboration to continuously improve and innovate in our methods and tools.
Our team gathers management excellence and top scientific expertise that can be traced back to the founding of fully human antibody phage display libraries.
Bernard Pau PhD
Founder / Chief Executive Officer
Hon. Professor, Immunology, U-Montpellier.
Former Head of Dpt Life Sciences CNRS, Paris.
Top management, entrepreneur, expert in the development of Biotech & Pharma innovation.
Gautier Robin PhD
Founder / Chief Scientific Officer
PhD at University Joseph Fourier, Grenoble (Prof. R. H. Wade)
20 years of experience in academic and biotech research and management.
Expert in protein engineering and phage display.
25 years experience working as CFO for start-ups primarily in the biotech sector.
Raised > €150 million from international investor base and €50 million via IPO.
Negotiated the sale of Novexel for $500 million.
Pierre Martineau PhD
Engineer Polytechnique school.
PhD at Biotechnology Department, Institut Pasteur, Paris (Prof. M. Hofnung).
PostDoc at Cambridge (UK) Center for Protein Engineering (Sir G. Winter).
Team leader Inserm (IRCM, Montpellier).
Deputy Director, IRCM.
Bruno Robert PhD
PhD at University Montpellier (Dr. A. Pelegrin)
PostDoc at University of Lausanne (CH), Department of Biochemistry (Prof. J-P. Mach)
Inserm Scientist (IRCM, Montpellier)
Sylvain Yon PhD
Strategic and business development advisor
20 years of experience in medical devices and biotechnology startups. He is a co-founder of Echosens where he managed Technology and was chairman of the board until 2011. He is currently Deputy CEO of Theraclion, a public company developing solutions for non-invasive surgery. Sylvain is also an active business angel and strategic consultant for some very promising ventures in healthcare. He holds an engineering degree from ESPCI ParisTech and a PhD from Paris Diderot University.
iMAb, Institut de Recherche en Cancérologie de Montpellier, Campus Val d'Aurelle, 34298 Montpellier cedex 5, France